Abemaciclib▼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Article Metrics

CPD  Back to article

Abemaciclib▼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

Related articles

Side effects of pazopanib in renal cell carcinoma
This article provides practical guidance for oncology nurses...

Chronic pain in breast cancer survivors
The 20-year relative survival rate for women diagnosed with...

Services for women with metastatic breast cancer in the US
This article describes the experience of a nurse on an...

The value of service user feedback
Wales Cancer Research Network was invited to host a patient...

The biology of cancer
Cancer research is moving fast. Understanding of the biology...